16 results about "Corilagin" patented technology

The invention discloses an application of an RUNX2 inhibitor in preparation of a medicine for treating vascular calcification related diseases, and the RUNX2 inhibitor comprises an ester compound which is selected from at least one of Corilagin, 1, 2, 3, 6-tetragalloylglucose, NADP (Nicotinamide Adenine Dinucleotide Phosphate), Stafib-2 and uridine triphosphate sodium salt. The ester compound provided by the invention is used as a drug for inhibiting vascular calcification and progression of the RUNX2 inhibitor, and provides a new thought, a target spot and a small molecule drug for treatment of vascular calcification. The five small molecule compounds have good drug safety and a strong vascular calcification inhibition effect, and can be used as candidate drugs for inhibiting vascular calcification.

The invention belongs to the technical field of traditional Chinese medicine detection, and particularly relates to a method for determining the content of multiple components in gout pills, which adopts high performance liquid chromatography to simultaneously determine the content of effective components such as aesculin, syringin, corilagin, ellagic acid and chebulilic acid in the gout pills, and adopts ultraviolet spectrophotometry to determine the content of total alkaloids in the gout pills. The method can effectively shorten the analysis time of main effective components in the gout pills, has a good linear range, is high in accuracy, precision and repeatability, is stable and feasible, and can be applied to content determination and quality standard of the gout pills.

The invention discloses an application of corilagin in preparation of a medicine for treating and / or preventing a non-alcoholic fatty liver disease. It is proved for the first time that corilagin can reduce lipid accumulation and inhibit oxidative stress through an Nrf2-ARE endogenous antioxidant pathway, has an obvious improvement effect on the non-alcoholic fatty liver disease, and it is proved that corilagin is expected to serve as an alternative medicine for treating the NAFLD, and the corilagin can be used as a medicine for treating the NAFLD. The potential application value is realized on the improvement and treatment of the NAFLD disease.

This invention relates to the field of traditional Chinese medicine analysis, and particularly to a method for determining the content of multiple components in Terminalia chebula and constructing its characteristic fingerprint spectrum. The method provided by this invention can simultaneously determine chebulin, gallic acid, 4-galloshikimic acid, 5-galloshikimic acid, punicalin (punicalin A&B), corilagin, 1,3,6-tri-O-galloyl-β-D-glucose, chebulin, urolithin M5, chebulin tannic acid, chebulin-lintannic acid, and ellagic acid in Terminalia chebula. It exhibits high sensitivity, good precision, repeatability, and stability, and can be used to detect the tannin content in the extract at each step of the tannin extraction process, as well as for related detection in the study and quality evaluation of tannin components in Terminalia chebula. It can also be used to construct the characteristic fingerprint spectrum of Terminalia chebula. This method can also be used for determining the content of tannin compounds and constructing their characteristic fingerprint spectrum in Terminalia chebula, which contains similar tannin compounds to Terminalia chebula.

The invention discloses an emblic leafflower fruit milk processing technology optimization method based on a single factor and pharmacodynamic experiment, and belongs to the technical field of traditional Chinese medicine processing, and the method comprises the following steps: screening out optimal technological parameters through the single factor experiment: mixing emblic leafflower fruit and raw milk according to a material-liquid ratio of 1: 15, soaking at 45 + / -5 DEG C for 12 hours, cleaning milk stains, naturally air-drying for 2 hours, and drying at 50 DEG C for 24-48 hours until the water content is less than 6%. A liquid chromatography-tandem high-resolution mass spectrometry technology is adopted for analysis and displaying that the content of gallic acid, ellagic acid and corilagin in a processed product is remarkably reduced. Pharmacodynamic experiments prove that the toxicity of the processed product to WRL68 hepatocytes and 293T renal cells is weakened, the survival rate of the hepatocytes and the renal cells is increased along with reduction of the concentration of the components, and the toxicity reduction effect is achieved. The technological parameters are clear, the quality is stable, and a scientific basis is provided for standardized production and clinical safe medication of emblic leafflower fruit milk processing.

The embodiment of the invention discloses application of a composition in preparation of a retinoic acid receptor gamma agonist and an external skin care product containing the composition. The composition comprises one or more of cyasterone, geraniin and corilagin. The embodiment of the invention further discloses application of the composition in preparation of a retinoic acid binding protein 2 agonist. The invention also discloses an application of the prepared retinoic acid receptor gamma agonist or retinoic acid binding protein 2 agonist in preparation of a photoaging skin cell protection composition.

The present invention discloses a method for purifying kolidinol diol, comprising the following steps: 1) adding 20 Kg of crude product into the reaction chamber, then gradually adding 22 L of methanol into the reaction chamber, and simultaneously gradually adding 0.6 - 1 L of concentrated hydrochloric acid to form a premixed material; 2) heating the reaction chamber to keep the premixed material in the reaction chamber boiling, and using the method of heating under reflux to completely dissolve the crude product to form a reaction solution; 3) maintaining the temperature in the reaction chamber between -1 and 1 °C, and then adding saturated sodium bicarbonate solution into the reaction chamber to neutralize the reaction solution; 4) controlling the temperature of the reaction chamber to be 100 - 105 °C to complete vacuum concentration. After the concentration is completed, adding chloroform into the reaction chamber, setting the temperature of the reaction chamber to 70 - 85 °C for heating and dissolving. When all is dissolved, controlling the discharge valve at the discharge port provided on the reaction chamber to open, and filtering at a temperature not lower than 60 °C inside the filtering device, and inputting the filtrate into the precipitation device, and cooling and crystallizing in the precipitation device.

The invention discloses a quality control method for Amaranthus tricolor, comprising the following steps: (1) preparing a test solution; using Amaranthus tricolor as a control medicinal material, preparing a control medicinal material reference solution; using gallic acid, corilagin, and ellagic acid as reference substances, respectively preparing reference substance reference solutions; (2) respectively drawing the reference medicinal material reference solution, the reference substance reference solution, and the test solution for ultra-high performance liquid chromatography analysis, constructing a corresponding characteristic spectrum, selecting 6 characteristic peaks in the characteristic spectrum of the test solution corresponding to the retention time in the characteristic chromatogram of the control medicinal material solution as common characteristic peaks, constructing a characteristic spectrum of Amaranthus tricolor, wherein characteristic peak 1 corresponds to the gallic acid reference substance peak, characteristic peak 4 corresponds to the corilagin reference substance peak, and characteristic peak 6 corresponds to the ellagic acid reference substance peak; (3) performing qualitative analysis on the test solution through the characteristic spectrum obtained in step (2). The method of the invention has good reproducibility and stability and reliable recovery rate.

The invention discloses a corilagin molecular imprinting electrochemical sensor as well as a preparation method and application thereof. The sensor comprises a glassy carbon electrode substrate, a boric acid functionalized Mxene conductive affinity composite material layer covering the glassy carbon electrode substrate and a corilagin molecularly imprinted polymer layer located on the surface of the boric acid functionalized Mxene conductive affinity composite material layer. The preparation method comprises the following steps: preparing a boric acid functionalized Mxene composite material and preparing a modification liquid; dispensing the modified liquid on the pretreated glassy carbon electrode to prepare a modified electrode; immobilizing corilagin template molecules through boric acid affinity reaction; carrying out surface molecular imprinting polymerization; and eluting the template molecules to form an imprinting cavity, thereby obtaining the sensor. The sensor disclosed by the invention has excellent conductivity, high selectivity and high sensitivity by constructing an integrated structure of a conductive nano skeleton and a dual recognition layer, and is wide in corilagin detection linear range, low in detection limit and good in stability.

The invention relates to a preparation method of a phyllanthus emblica fruit juice polyphenol extract, in particular to a method for extracting polyphenol from phyllanthus emblica fruit juice by utilizing an ultrasonic-assisted aqueous two-phase extraction technology. The method relates to an aqueous two-phase reagent for preparing the phyllanthus emblica fruit juice polyphenol extract, the aqueous two-phase reagent comprises phyllanthus emblica fruit juice, ethanol and ammonium sulfate, the volume ratio of the phyllanthus emblica fruit juice to the ethanol is 1: (1.5-7), and the volume ratio of the ammonium sulfate to the phyllanthus emblica fruit juice is 0.5-2.5 g / mL. Placing the aqueous two-phase reagent in an ultrasonic treatment device, and carrying out sufficient ultrasonic treatment; and separating the aqueous two-phase reagent subjected to ultrasonic treatment, and taking an upper phase part which comprises total polyphenol, total polysaccharide, vitamin C, gallic acid, corilagin, chebulagic acid and ellagic acid. According to the extraction method provided by the invention, the problem that hydrolyzed tannin is reduced in a traditional method is avoided, so that relatively high polyphenol extraction rate and quality can be kept, and the extraction method has relatively high practical value and market prospect.

The present invention provides the use of iota-carrageenan as an astringent flavoring agent for masking plant extracts containing corilagin. The invention also provides a phyllanthus emblica composition and a method for screening astringent substances in phyllanthus emblica juice. The iota-carrageenan is used as an astringent flavoring agent for masking the astringent taste of the corilagin-containing plant extract for the first time, in addition, a taste masking method of the emblic leafflower fruit juice is established, the serious sour and astringent taste of the emblic leafflower fruit juice is effectively reduced, changes of chemical components and physicochemical properties of the emblic leafflower fruit juice before and after taste masking and a masking mechanism are studied, and the taste of the emblic leafflower fruit juice is masked. Change characteristics and mechanisms of astringent substances in the taste masking process are clarified, so that a new research thought and technical reference are provided for promoting development of the phyllanthus emblica industry in the southwest region, and high-quality rapid development of the phyllanthus emblica industry chain is promoted.

The invention discloses a thin-layer identification method of a geranium wilfordii standard decoction, which comprises the following steps: preparing a test solution from the geranium wilfordii standard decoction, preparing a reference medicinal material solution from a geranium wilfordii reference medicinal material, and preparing a reference substance solution from a corilagin reference substance; spreading the test solution, the reference medicinal material solution and the reference substance solution by using a thin-layer plate, performing color development, inspecting under sunlight, and identifying according to spots; wherein a mixed solution of glacial acetic acid, ethanol, ethyl acetate and formic acid is used as a developing solvent, and a ferric trichloride ethanol solution is used as a color developing agent. According to the identification method provided by the invention, the geranium wilfordii standard decoction with different bases can be rapidly identified.

The invention provides a method for detecting multiple active ingredients in fructus chebulae immaturus and application. According to the present invention, the aqueous solvent extraction method is performed on the fructus chebulae immaturus powder, such that the acetonitrile and the aqueous solution containing 0.04-0.06% of formic acid are adopted to determine the mobile phase system and the gradient elution process, and the simultaneous detection of the six active components such as gallic acid, punicalagin (punicalagin A and punicalagin B), corilagin, myrobalan tannic acid, ellagic acid and myrobalan acid in the fructus chebulae immaturus can be achieved within 40 min. The method for determining the content of the terminalia chebula hance has the advantages that the method is high in precision, repeatability, specificity and stability, high in practical operability, low in cost and short in detection time, quality controllability of terminalia chebula hance medicinal materials and preparations thereof is guaranteed, and scientific basis is provided for quality control and standardization of terminalia chebula hance.

This invention discloses a novel use of corilagin or a pharmaceutically acceptable salt thereof in the preparation of medicaments for the treatment and / or prevention of human papillomavirus (HPV) infection and related diseases. This invention is the first to discover and demonstrate that corilagin can downregulate the expression of HPV E6 and / or E7 oncogenic proteins, thereby inhibiting viral activity and blocking the malignant transformation process driven by the virus. Based on this original discovery, corilagin or a pharmaceutically acceptable salt thereof can be used to prepare medicaments or pharmaceutical compositions for the prevention and / or treatment of persistent HPV infection, reversal of cervical intraepithelial neoplasia, adjuvant therapy for cervical cancer, and treatment of other HPV-related diseases (including but not limited to oropharyngeal HPV infection, anal HPV infection, vulvar intraepithelial neoplasia, etc.), preferably prepared as a mucosal topical dosage form. This discovery provides a novel, structurally well-defined small molecule drug candidate for the prevention and treatment of HPV-related diseases.

The invention relates to application of corilagin in preparation of a staphylococcus aureus inhibitor. Experiments prove that corilagin is directly combined with staphylococcus aureus cell wall hydrolase, so that bacterial proliferation is slowed down, and biofilm formation is reduced; the hemolytic activity of the alpha-hemolysin protein and the bacterial culture supernatant can be reduced through two ways of directly inhibiting the staphylococcus aureus alpha-hemolysin and inhibiting the secretion of the staphylococcus aureus alpha-hemolysin to the culture medium supernatant; corilagin has no cytotoxic effect, and can significantly inhibit human pulmonary epithelial cell-mediated cytotoxicity and adhesion effect of staphylococcus aureus; by constructing a staphylococcus aureus infected mouse pneumonia model, it is found that corilagin remarkably improves the survival rate of infected mice, colonization of staphylococcus aureus in mice lungs is reduced, and edema and inflammatory response of the mice lungs are relieved. The results show that corilagin has a good application prospect in the aspect of resisting staphylococcus aureus infection.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a geranian extract, a preparation method thereof and an application of the geranian extract in resisting rheumatoid arthritis, dry geranian powder is subjected to ethanol extraction and then is subjected to liquid separation extraction with ethyl acetate to obtain a geranian ethyl acetate extract with anti-inflammatory activity, and the geranian ethyl acetate extract is subjected to silica gel column chromatography separation and purification to obtain the geranian extract with anti-inflammatory activity. The geranian extract which contains ellagic acid, geraniin and corilagin and has remarkable anti-inflammatory activity is separated from the geranian extract, and the geranian extract has a remarkable improvement effect on rheumatoid arthritis. The invention provides an efficient and low-toxicity plant extract for developing medicines for improving rheumatoid arthritis, the source of the raw material geranian is convenient, the extraction method is simple and convenient, the cost is low, the geranian extract containing ellagic acid, geraniin and corilagin has development potential in the aspect of treating inflammation, and the geranian extract containing ellagic acid, geraniin and corilagin has a wide application prospect. The compound can be applied to the development of efficient and low-toxicity plant-derived anti-inflammatory agents.